Organon & Co. Proceeds from Long-Term Debt Issued
Organon & Co. (OGN) reported Proceeds from Long-Term Debt Issued of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-07-31
- Organon & Co. proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Organon & Co. proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Organon & Co. proceeds from issuance of long-term debt for the quarter ending 2025-12-31 was $325.00M, a 116.67% increase year-over-year.
- Organon & Co. proceeds from issuance of long-term debt for the quarter ending 2025-09-30 was $300.00M.
- Organon & Co. proceeds from issuance of long-term debt for fiscal 2025 was $1.05B, a 11.05% decline from fiscal 2024.
- Organon & Co. proceeds from issuance of long-term debt for fiscal 2024 was $1.19B, a 1382.50% increase from fiscal 2023.
- Organon & Co. proceeds from issuance of long-term debt for fiscal 2023 was $80.00M.
- Organon & Co. proceeds from issuance of long-term debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $0.00 10-Q · filed 2026-07-31 | $325.00M derived: sum of 3 quarters · filed 2026-07-31 | $625.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-04 | $325.00M derived: sum of 2 quarters · filed 2026-05-04 | $625.00M derived: sum of 3 quarters · filed 2026-05-04 | $965.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $325.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $625.00M derived: sum of 2 quarters · filed 2026-02-24 | $965.00M derived: sum of 3 quarters · filed 2026-07-31 | $1.05B 10-K · filed 2026-02-24 |
| 2025-09-30 | $300.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $640.00M derived: sum of 2 quarters · filed 2026-07-31 | $730.00M 10-Q · filed 2025-11-10 | $880.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $340.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $430.00M 10-Q · filed 2026-07-31 | $580.00M derived: sum of 3 quarters · filed 2026-07-31 | $580.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $90.00M 10-Q · filed 2026-05-04 | $240.00M derived: sum of 2 quarters · filed 2026-05-04 | $240.00M derived: sum of 3 quarters · filed 2026-05-04 | $1.28B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $150.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $150.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.19B derived: sum of 3 quarters · filed 2026-02-24 | $1.19B 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.04B derived: sum of 2 quarters · filed 2025-11-10 | $1.04B 10-Q · filed 2025-11-10 | $1.04B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.04B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.04B 10-Q · filed 2025-08-06 | $1.04B derived: sum of 3 quarters · filed 2026-02-24 | $1.04B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-02 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $80.00M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $80.00M 10-Q · filed 2024-11-01 | ||
| 2023-06-30 | $80.00M 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $9.47B 10-K · filed 2024-02-26 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $9.47B 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | $9.47B 10-Q · filed 2022-08-05 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |